Evaluation of Circulating Tumor DNA as a Biomarker for Chemoresistance in Colorectal Cancer
Koduvayur Roopa Lakshmi, Charan Sankar Sankaranarayanan, Raja A. S. Gogineni, K. Afsar Shaheen, Parasharan Peddi · 2025
Read Evaluation of Circulating Tumor DNA as a Biomarker for Chemoresistance in Colorectal Cancer by Koduvayur Roopa Lakshmi, Charan Sankar Sankaranarayanan, Raja A. S. Gogineni, K. Afsar Shaheen, Parasharan Peddi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12788532.txt.
Description
Koduvayur Roopa Lakshmi and co-authors present a biomarker study, published in 2025, on reading tumor DNA in the blood to foresee chemotherapy failure in bowel cancer. Ninety-six patients with stage two to four disease began the standard FOLFOX regimen while the team sampled their blood before treatment and after the third and sixth cycles. Just over a third proved resistant to the drugs.
Resistant patients started with markedly more tumor DNA in their blood, and mutations in the TP53 gene were twice as common among them. A clear drop in tumor DNA by the third cycle flagged the responders well. The authors propose blood based monitoring as an early warning that a regimen is failing, months before scans confess it.
Catalog record
| CREATOR | Koduvayur Roopa Lakshmi, Charan Sankar Sankaranarayanan, Raja A. S. Gogineni, K. Afsar Shaheen, Parasharan Peddi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |